These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21742770)

  • 1. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
    Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
    Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
    Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
    Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
    Azoitei N; Hoffmann CM; Ellegast JM; Ball CR; Obermayer K; Gößele U; Koch B; Faber K; Genze F; Schrader M; Kestler HA; Döhner H; Chiosis G; Glimm H; Fröhling S; Scholl C
    J Exp Med; 2012 Apr; 209(4):697-711. PubMed ID: 22451720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
    Luo T; Masson K; Jaffe JD; Silkworth W; Ross NT; Scherer CA; Scholl C; Fröhling S; Carr SA; Stern AM; Schreiber SL; Golub TR
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2860-5. PubMed ID: 22323609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STK33 kinase is not essential in KRAS-dependent cells--letter.
    Fröhling S; Scholl C
    Cancer Res; 2011 Dec; 71(24):7716; author reply 7717. PubMed ID: 22127923
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
    Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
    Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
    Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.
    Weïwer M; Spoonamore J; Wei J; Guichard B; Ross NT; Masson K; Silkworth W; Dandapani S; Palmer M; Scherer CA; Stern AM; Schreiber SL; Munoz B
    ACS Med Chem Lett; 2012 Dec; 3(12):1034-1038. PubMed ID: 23256033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
    Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction.
    Sun EL; Liu CX; Ma ZX; Mou XY; Mu XA; Ni YH; Li XL; Zhang D; Ju YR
    Neoplasma; 2017; 64(6):869-879. PubMed ID: 28895411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
    Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
    Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential.
    Wang P; Cheng H; Wu J; Yan A; Zhang L
    Acta Biochim Biophys Sin (Shanghai); 2015 Mar; 47(3):214-23. PubMed ID: 25662617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
    Sun C; Hobor S; Bertotti A; Zecchin D; Huang S; Galimi F; Cottino F; Prahallad A; Grernrum W; Tzani A; Schlicker A; Wessels LF; Smit EF; Thunnissen E; Halonen P; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Trusolino L; Bernards R
    Cell Rep; 2014 Apr; 7(1):86-93. PubMed ID: 24685132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.